Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
What specific pattern of treatment response failures do you require to switch a patient from a TNFI to an IL-6 inhibitor of co-stimulatory blockade?
Video
Can you summarize the key features of the new guidelines for RA issued by the ACR?
Can you summarize the key features of the new guidelines for RA issued by the ACR?
Video
What is the role of B-cell depletion therapy in RA?
What is the role of B-cell depletion therapy in RA?
Video
Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? What are the findings and why is this important?
Video
How important are quality-of-life measures in RA and how effective are IL-6 inhibitors in this regard compared to TNFIs according to the latest clinical studies?
Video
Do the trials with the IL-6 inhibitor sarilumab suggest any differences between this agent and the establish IL-6 inhibitor indicated for RA?
Video
With respect to clinical response, what is the trigger for using a different MOA — including IL-6 inhibition — in a patient who has failed a TNFI?
Video
What clinical trials have been conducted and/or are currently in progress evaluating IL-6 inhibitors for the management of RA? How are the trials designed with respect to identifying patients most suitable for IL-6 inhibition?
Video
What is the precise immunopathobiologic mechanism of action for agents targeting IL-6 in the setting of RA? What are the implications for using IL-6 inhibitors as monotherapy?
Video
What role do the following factors play in identifying high-risk patients with RA, and what are the clinical implications of stratifying patients using these biological or clinical markers? Disease duration? High titer of RF? Elevated ...
